Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting
Clinical and Molecular Studies in Families With Inherited Eye Disease
Study identifying genetic causes of inherited eye diseases through clinical examination, electrical eye testing, and blood/saliva genetic analysis.
14 Apr 2026 NCT02771236
active not recruiting Oncology
Does Screening With the Galleri Test in the NHS Reduce the Likelihood of a Late-stage Cancer Diagnosis in an Asymptomatic Population? A Randomised Clinical Trial
Blood test screening alongside standard NHS testing detected more early-stage cancers and fewer late-stage cancers in asymptomatic adults.
14 Apr 2026 NCT05611632
● Recruiting Phase II
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
Long-term safety and efficacy study of lunsekimig (a new treatment) in adults with poorly controlled chronic rhinosinusitis with nasal polyps over 52 weeks.
14 Apr 2026 NCT06914908
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very…
14 Apr 2026 NCT06883305
● Recruiting Respiratory / COPD / Asthma
Eosinopenia in Severe COPD Exacerbation
The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive…
14 Apr 2026 NCT06188065
● Recruiting Phase IV Cardiology / Cardiovascular
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
Multinational, investigator-initiated study of oral anticoagulation versus no anticoagulation for the prevention of stroke and other adverse cardiovascular events in patients with transient atrial…
14 Apr 2026 NCT03968393
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired…
14 Apr 2026 NCT06056297
● Recruiting Phase I Oncology
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in…
14 Apr 2026 NCT06253871
● Recruiting Phase III Oncology
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a…
14 Apr 2026 NCT06750094
● Recruiting Phase III Oncology
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil,…
14 Apr 2026 NCT06662786
● Recruiting Phase I Oncology
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
14 Apr 2026 NCT05413850
● Recruiting Phase I Oncology
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1…
14 Apr 2026 NCT07319871
● Recruiting Phase I Oncology
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in…
14 Apr 2026 NCT06190899
● Recruiting Phase III Oncology
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of…
14 Apr 2026 NCT07225946
● Recruiting Phase I Oncology
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1…
14 Apr 2026 NCT07082920
● Recruiting Phase II Oncology
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with…
14 Apr 2026 NCT02960022
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity)…
14 Apr 2026 NCT06667076
● Recruiting Phase II Oncology
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant…
14 Apr 2026 NCT05498428
● Recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or…
14 Apr 2026 NCT06793215
● Recruiting Phase II Oncology
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with…
14 Apr 2026 NCT07368998
● Recruiting Phase I Oncology
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy…
14 Apr 2026 NCT05238922
● Recruiting Neurology
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in…
14 Apr 2026 NCT02071134
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants…
14 Apr 2026 NCT05797610
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a…
14 Apr 2026 NCT05457283
● Recruiting Phase III
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative…
14 Apr 2026 NCT03955445
● Recruiting Phase III Rheumatology
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or…
14 Apr 2026 NCT06663332
● Recruiting Phase II Rheumatology
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn’s Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to…
14 Apr 2026 NCT06233461
● Recruiting Phase III Rheumatology
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult…
14 Apr 2026 NCT07196748
● Recruiting Respiratory / COPD / Asthma
Biologics and Paediatric Enteral Nutrition in Crohn’s Disease Study
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections…
14 Apr 2026 NCT07522528
● Recruiting Respiratory / COPD / Asthma
The PARS Study: Paediatric Advanced Respiratory Service Study – An Observational Diagnostic Feasibility Study
Diagnostic investigations in paediatric respiratory and sleep medicine are often challenging due to patient size (due to prematurity), tolerability, and compliance with "gold standard…
14 Apr 2026 NCT06292299
● Recruiting Respiratory / COPD / Asthma
Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets
The goal of this study is to examine exacerbations of chronic obstructive pulmonary disease (COPD) caused by a common cold virus called rhinovirus, to…
14 Apr 2026 NCT07112235
● Recruiting Respiratory / COPD / Asthma
Capillary OGTT Study
Type 1 diabetes (T1D) is a chronic condition, affecting 1 in 490 children under the age of 15 years. It is caused by the…
14 Apr 2026 NCT06815081
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
14 Apr 2026 NCT05702034
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity…
14 Apr 2026 NCT07179380
● Recruiting Cardiology / Cardiovascular
Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
The objective of this study is to evaluate real world long-term functional outcomes, safety and performance of the Indigo Aspiration System for the treatment…
14 Apr 2026 NCT04798261
● Recruiting Phase I Oncology
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide)…
14 Apr 2026 NCT07206056
● Recruiting Phase II Oncology
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy…
14 Apr 2026 NCT06667908
● Recruiting Phase I Oncology
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116…
14 Apr 2026 NCT05142189
● Recruiting Phase III Oncology
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients…
14 Apr 2026 NCT05671510
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or…
14 Apr 2026 NCT06615479
● Recruiting Phase III Oncology
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients…
14 Apr 2026 NCT06380751
● Recruiting Phase II Oncology
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
14 Apr 2026 NCT07023627
● Recruiting Phase II Oncology
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Two drug combinations tested for advanced lung cancer with EGFR mutations: amivantamab plus lazertinib versus amivantamab plus chemotherapy.
13 Apr 2026 NCT06667076
● Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
Global registry tracking anemia risk in babies of mothers at risk for blood incompatibility disease receiving standard care.
13 Apr 2026 NCT07194070
active not recruiting Phase III
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
CAR-T cell therapy cilta-cel compared with standard chemotherapy in patients with relapsed multiple myeloma resistant to lenalidomide.
13 Apr 2026 NCT04181827
● Recruiting Phase III
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Trial testing whether adding bleximenib to venetoclax-azacitidine improves outcomes in newly diagnosed AML with specific genetic mutations.
13 Apr 2026 NCT06852222
active not recruiting
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
ATTUNE® Revision knee implants showed good five-year outcomes in complex primary knee replacement surgery using fixed or rotating tibial components.
13 Apr 2026 NCT03153449
active not recruiting Phase III Oncology
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
Adding niraparib to standard prostate cancer treatment (abiraterone and prednisone) delays cancer progression compared to standard treatment alone.
13 Apr 2026 NCT03748641
active not recruiting Phase II Cardiology / Cardiovascular
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
Trial testing a new drug combination for heart-involved amyloid disease, comparing immediate versus delayed treatment timing.
13 Apr 2026 NCT05250973
● Recruiting Phase II / Phase III
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
Aficamten improves symptoms and safety in children with obstructive hypertrophic cardiomyopathy, a serious heart muscle condition.
13 Apr 2026 NCT06412666